



Correction: American College of Medical Toxicology and the American Academy of Clinical Toxicology Position Statement: Nalmefene Should Not Replace Naloxone as the Primary Opioid Antidote at This Time

Andrew I. Stolbach¹ · Maryann Mazer-Amirshahi² · Lewis S. Nelson³ · Jon B. Cole⁴

Published online: 28 December 2023
© American College of Medical Toxicology 2023

Correction: *Journal of Medical Toxicology*

<https://doi.org/https://doi.org/10.1007/s13181-023-00981-z>

In the article as originally published, Table 1 contained a transposition error. The T_{max} for naloxone IN should have been 0.5 h and the T_{max} for nalmefene IN should have been 0.25 h.

The authors and the journal respectfully apologize for this error.

The original article has been corrected.

Table 1 Comparison of naloxone and nalmefene

	Naloxone IN	Naloxone IV	Nalmefene IN
T _{1/2} (h)	2.08	0.5—1.5	7.11
T _{max} (h)	0.5	Nearly instantaneous	0.25
K _i (nM)	5.4	5.4	1.0
Wholesale Acquisition Cost (\$)	\$64.80—75/nasal administration [2-pack]	\$5.27—23.72/mL of 0.4 mg/mL solution	\$98 [2-pack]

T_{1/2} Serum half-life (Not a direct measure of duration of action, but may correlate with duration of action)

T_{max} Time of maximum serum concentration

K_i Inhibitor constant; inversely proportional to receptor affinity, not dependent on route of administration

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The original article can be found online at <https://doi.org/10.1007/s13181-023-00981-z>.

✉ Andrew I. Stolbach
positionstatements@acmt.net

¹ Johns Hopkins University School of Medicine, Baltimore, MD, USA

² MedStar Washington Hospital Center, Washington, DC, USA

³ Department of Emergency Medicine, Rutgers New Jersey Medical School, Newark, NJ, USA

⁴ Minnesota Poison Control System, Departments of Emergency Medicine, Hennepin Healthcare and University of Minnesota Medical School, Minneapolis, MN, USA